ArticleMicrobiology spectrum2025
Impact of multiplex polymerase chain reaction testing in patients with bacteremia.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rapid Detection of Pathogens and Resistance Genes in Positive Blood Cultures Using BioFirePolish journal of microbiology · 2026Article
- Balancing Speed and Cost: Economic Insights from Rapid Diagnostic Testing in Bloodstream Infections.Antibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid identification of pathogens in bacteremia is critical for optimizing antimicrobial therapy. The FilmArray blood culture identification 2 (BCID2) panel enables multiplex PCR-based detection of pathogens and resistance genes. This study aimed to evaluate the clinical impact of BCID2 implementation in hospitalized patients with bacteremia. To this end, we conducted a retrospective study at a single Japanese center (May 2018-December 2024). The outcomes included length of stay, in-hospital mortality, antimicrobial days of therapy (DOT), and days of antimicrobial spectrum coverage (DASC) score. The pre-BCID2 and BCID2 implementation periods were compared. Among the 2,872 patients with positive blood cultures, BCID2 implementation was associated with a significant reduction in mortality (adjusted odds ratio [aOR] 0.58, 95% CI: 0.37-0.92,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.